Impact Biotech
Healthcare™
With access to scientific and clinical experts, IBH can provide the most up-to-date technologies in emerging health-related fields.
IBH identifies healthcare challenges faced by those most in need and provides opportunities to make informed decisions concerning health and treatment options.
Offering the tools needed to make the best choices that will enable the highest impact on overall health and wellbeing.
Our vision is to make innovative life sciences technologies available for all, providing evidence-based and personalised health management solutions.
cPass™
We are proud to offer cPass™, the first rapid test kit for measuring neutralising antibodies against SARS-CoV-2.
cPass™ and cPass Express™ (RUO) are tests that measure the level of Neutralising Antibodies (NAb) in blood. NAb actively block the COVID-19 virus from binding to cells, providing the most accurate indication of immunity (as a correlate of protection) against the virus.
Individual Booster Requirements
Risk Stratification
IBH has distribution rights to commercialise, launch and supply cPass™ and cPass Express™ in Australia, New Zealand, South Pacific Islands, Bangladesh, Philippines and Indonesia.
Immuno-compromised and elderly
International Travel
Directors
Our Partners
